MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2023 International Congress

    Characterization of the pathogenic α-Synuclein variant p.V15A in Parkinson´s disease

    S H. Diaw, F. Buratti, L. Streubel-Gallasch, M. Borsche, M. Dulovic-Mahlow, C O. Fernández, J. Seeliger, I. Lenz, P. Seibler, C. Klein, N. Brüggemann, M. Zweckstetter, M. Vos, K. Lohmann (Lübeck, Germany)

    Objective: To investigate functional alterations of the p.V15A variant in alpha-Synuclein (α-Syn) in Parkinson's disease (PD). Background: PD is marked by the loss of dopaminergic…
  • 2023 International Congress

    The characterization of Parkinson’s disease related nociplastic pain based on the classification system

    T. Tezuka, T. Nukariya, S. Okusa, Y. Nihei, J. Nakahara, M. Seki (Tokyo, Japan)

    Objective: The characteristics of Parkinson’s disease (PD)-related nociplastic pain were evaluated by using various indicators including PD pain classification system (PD-PCS), King's Parkinson Disease Pain…
  • 2023 International Congress

    Novel modifiers of heterozygous pathogenic Parkin variant penetrance in Parkinson’s disease

    A. Hach, Z. Landoulsi, B. Meier, P. Seibler, C. Klein, P. May, A. Rakovic (Luebeck, Germany)

    Objective: To identify novel genes and pathways acting as modifiers of pathogenic Parkin variant (PV) penetrance in affected compared to unaffected carriers of heterozygous Parkin PVs…
  • 2023 International Congress

    A 16-week open-label study of the effects of treatment with pimavanserin on activities of daily living in subjects with Parkinson’s disease psychosis (PDP)

    V. Evidente, D. Dekarske, B. Coate, V. Abler (Scottsdale, USA)

    Objective: To examine the effects of pimavanserin on activities of daily living during treatment for Parkinson’s Disease psychosis. Background: Accurate assessment of disability associated with…
  • 2023 International Congress

    Olfactory dysfunction as a predictor of the future development of parkinsonism in COVID patients

    M. de Rosa, D. Calisi, L. Bonanni, M. Onofrj (Chieti, Italy)

    Objective: Olfactory dysfunction due to SARS-CoV-2 infection as a prodromal stage of PD. Background: Olfactory dysfunction due to SARS-CoV-2 disease can depend on the neuroinvasive properties…
  • 2023 International Congress

    Bilateral subthalamic nucleus deep brain stimulation in Parkinson’s disease: preoperative predictors of speech worsening

    F. Cavallieri, F. Bove, A. Zampogna, A. Castrioto, S. Meoni, A. Gessani, E. Schmitt, A. Bichon, E. Lhommée, P. Pélissier, A. Kistner, E. Chevrier, F. Valzania, E. Seigneuret, S. Pinto, S. Chabardès, V. Fraix, E. Moro (Reggio Emilia, Italy)

    Objective: To find preoperative predictive factors of short-term postoperative speech worsening in a large cohort of consecutive PD patients treated with bilateral STN-DBS. Background: Subthalamic…
  • 2023 International Congress

    6-[18F]fluoro-L-3,4-dihydroxyphenylalanine (F-DOPA) PET striatal binding patterns in patients with Parkinson’s Disease and Parkinson Plus Syndromes.

    A. Buckland, T. Lee, R. Stell, S. Ghosh, J. Rodrigues, W. Yau, S. Vijayan, R. Francis, K. Sek, L. Morandeau, A. Jacques, T. Hagan, J. Watts, E. Campbell, N. Loh (Nedlands, Australia)

    Objective: In this study we investigate striatal binding patterns in patients with Idiopathic Parkinson’s disease (IPD), compared to those with Parkinson Plus syndromes (PPS) versus…
  • 2023 International Congress

    Detection and classification of GBA variants PD-related: is there sex unbalance?

    C. Reale, C. Panteghini, I. Colangelo, M. Suerz, R. Cilia, R. Eleopra, B. Garavaglia, F. Invernizzi (Milan, Italy)

    Objective: This study aims to classify GBA variants detected in the Genetic Movement Disorders Laboratory (GMDL) of the Neurological Institute “Carlo Besta” in Milan over…
  • 2023 International Congress

    Concealment of Parkinson’s Disease: Prevalence and Impact on Health and Quality of Life

    G. Yogev-Seligmann, B. Naamneh Abuelhija, M. Giveon, M. Meir Kestenbaum, M. Kafri (Haifa, Israel)

    Objective: (1) To explore the proportion and personal characteristics of patients who do not disclose their diagnosis of Parkinson's disease (PD) to their family, and…
  • 2023 International Congress

    Effectiveness of speech therapy in patients with Parkinson’s disease – a randomized controlled trial

    J. Maas, N. de Vries, B. Bloem, H. Kalf (Nijmegen, Netherlands)

    Objective: We aimed to assess the effectiveness of speech therapy on improving quality of life and speech quality in patients with Parkinson’s disease. Background: Although…
  • « Previous Page
  • 1
  • …
  • 357
  • 358
  • 359
  • 360
  • 361
  • …
  • 553
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley